Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Wednesday. $127.21 million flowed into the stock on the tick-up and $296.24 million flowed out of the stock on the tick-down, for a money net flow of $169.03 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.72 for the day and closed at $142.36
JNJ has been the subject of several recent research reports. Morgan Stanley boosted their price target on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Cowen and Company reiterated an “outperform” rating and set a $155.00 target price (up from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS AG reiterated a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a research report on Thursday, August 31st. BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $143.70.
The stock has a 50-day moving average price of $134.68 and a 200 day moving average price of $131.18. The stock has a market capitalization of $376.78 billion, a price-to-earnings ratio of 24.41 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter last year, the business posted $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post $7.28 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.37%. Johnson & Johnson’s payout ratio is 58.33%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Harding Loevner LP purchased a new stake in Johnson & Johnson during the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC raised its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson during the second quarter valued at about $124,000. Institutional investors and hedge funds own 65.89% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/investors-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.